Atezolizumab

CAS No. 1380723-44-3

Atezolizumab ( —— )

Catalog No. M22134 CAS No. 1380723-44-3

Atezolizumab anti-PD-L1) is a fully humanized IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1 but not the interaction of PD-L2 with PD-1.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 489 In Stock
10MG 717 In Stock
25MG 1071 In Stock
50MG 1467 In Stock
100MG 1962 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Atezolizumab
  • Note
    Research use only, not for human use.
  • Brief Description
    Atezolizumab anti-PD-L1) is a fully humanized IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1 but not the interaction of PD-L2 with PD-1.
  • Description
    Atezolizumab anti-PD-L1) is a fully humanized IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1 but not the interaction of PD-L2 with PD-1.
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Other Targets
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1380723-44-3
  • Formula Weight
    145 kDa
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Inman BA, et al. Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer. Clin Cancer Res. 2017 Apr 15;23(8):1886-1890.
molnova catalog
related products
  • Berberine hydrochlor...

    An alkaloid from Hydrastis canadensis L., Berberidaceae. It is also found in many other plants.

  • Methyl lucidenate G

    Methyl lucidente G is a natural product for research related to life sciences.

  • Ufenamate

    Ufenamate is an anthranilic acid-based anti-inflammatory drug developed for skin diseases.